Press release
Melanoma Treatment Market expected to reach $5.64 billion by 2023 with 15.5% CAGR, Says MarketIntelReports
“Melanoma Global Clinical Trials Review, H1, 2016" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
Browse Melanoma Global Clinical Trials Review, H1, 2016 Research Report
http://www.marketintelreports.com/report/gdhc3214ctidb/melanoma-global-clinical-trials-review-h1-2016
MarketIntelReports latest report states that this impressive growth, which will occur across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK, Japan, and Australia, will be driven primarily by increasing sales of Bristol-Myers Squibb's blockbuster immunotherapy Yervoy.
"While Yervoy's sales will be negatively impacted by the first-line uptake of PD-1-targeting monoclonal antibodies (mAbs) Keytruda and Opdivo from 2015 to 2017, the approval of the Yervoy/Opdivo combination will recover the former's market position in the second half of the forecast period.
"Furthermore, Yervoy's label expansion into the lucrative adjuvant setting will further enhance its sales from 2019 onwards."
MarketIntelReports estimates sales of $889 million for Yervoy in the 8MM in 2013, and forecasts this to rise at a CAGR of 8.2% to $1.96 billion by 2023.
Some of the prominent players of market:
Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Merck & Co., Inc. Novartis AG AstraZeneca Plc Pfizer Inc. Ludwig Institute For Cancer Research Ltd Eisai Co., Ltd. Amgen Inc. and Others
The BRAF/MEK inhibitor combinations, in particular Novartis' Tafinlar/Mekinist and Roche/Exelixis' Zelboraf/cobimetinib, will replace standard BRAF inhibitor monotherapy of Zelboraf or Tafinlar. In addition, Keytruda and Opdivo will garner rapid growth in both BRAF mutated and wild-type settings.
"These novel agents and combinations will experience large uptake globally, thanks to their improved overall response rate and overall survival, along with their manageable side effect profiles. Notably, the combination treatments will fetch a higher premium price than monotherapies, which, on top of raising company sales, will also result in greater pushback from payers."
MarketIntelReports expects these new, more efficacious entrants to replace generic chemotherapy-only regimens in the first- and second-line settings, therefore driving the growth of the overall melanoma market and extending the lines of treatment available for patients.
"The launch of these improved agents will ensure that many patients receive one to two lines of treatment with branded premium-priced drugs by 2023 and beyond."
Request for Sample Brochure of Report @ http://www.marketintelreports.com/pdfdownload.php?id=gdhc3214ctidb
MarketIntelReports expects these new, more efficacious entrants to replace generic chemotherapy-only
About us:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
Contact us:
Sales Manager
Mayur S.
2711 Centerville Road, Suite 400, Wilmington,Delaware,19808
United States
www.marketintelreports.com
sales@marketintelreports.com
Telephone: 1-302-261-5343
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Melanoma Treatment Market expected to reach $5.64 billion by 2023 with 15.5% CAGR, Says MarketIntelReports here
News-ID: 350984 • Views: …
More Releases from MarketIntelReports
Study on Future Growth Drivers of the Cloud Integration Market
Cloud Integration or integration platform as a service (iPaaS) is one of the fast emerging forms of cloud computing services that are delivered to configure data with various application programs. These application programs range from enterprise risk management (ERM), customer relationship management (CRM), database management system (DBMS), and business process management to web conferencing, and emails, etc. Cloud integration services are especially designed to help organizations of all sizes to…
Analysis of Variables Pushing the Expansion of the Workforce Management Market
Workforce Management is an integrated set of processes that an institution or organization uses to optimize the productivity of its employees on the individual, departmental, and entity-wide levels.
This report identifies the Workforce Management market size in terms of value for the year 2014-2016, and forecast of the same for year 2021. It highlights potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges,…
Study on Future Growth Drivers of the Blockchain Market
The blockchain technology market size is estimated to grow from USD 210.2 Million in 2016 to USD 2,312.5 Million by 2021, at a Compound Annual Growth Rate (CAGR) of 61.5% during the forecast period. In the report, 2015 is considered the base year, while the forecast period is 2016–2021.
The objective of the report is to define, describe, and forecast the blockchain technology market on the basis of providers, applications, deployment…
Glass Bonding Adhesives Market by End-Use Industry (Furniture, Electronics, Medi …
The use of adhesives and glues as a bonding agent between glass and other materials is increasing now a days. The glass bonding adhesives has a wide range of applications in automotive industry for bonding the glass in vehicles, manufacturing of water tanks and optical glasses, bonding of window glass to frame or structure etc. The selection of a suitable adhesive for proper bonding of glass depends upon various factors…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
